comparemela.com

Latest Breaking News On - Prnewswire curis inc - Page 8 : comparemela.com

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesGrzegorz nowakowskiJames dentzerAndrey ugolkovGuillermo garcia maneroAmerican society of clinical oncologyDrug administrationUniversity of floridaEuropean hematology associationMd anderson cancer centerCuris incPrnewswire curis incRoche groupDevelopment of potential biomarkersInitial takeaim lymphomaTakeaim leukemia

Curis Reports First Quarter 2022 Financial Results and Business Update

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesRoche erivedgeJames dentzerAmerican society of clinical oncologyEuropean hematology associationDrug administrationWashington university school of medicineCuris incAmerican society of clinical oncology annual meetingDevelopment expensesExchange commissionPrnewswire curis incRoche groupWashington university in stWashington universityChief executive officer

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

Prnewswire curis incCompany fourthCompensation committeeFourth amendedIncentive plan

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

James dentzerPrnewswire curis incCompany takeaim leukemia phaseRoche groupDrug administrationCuris incTakeaim leukemia phaseTakeaim leukemiaRecommended phaseChief executive officerTakeaim lymphomaAim lymphomaAim leukemiaOrphan drug designation

Curis Announces Gastroenterolo - GuruFocus com

GuruFocus Article or News written by PRNewswire and the topic is about:

James dentzerGi oncology programDrug administrationWashington university school of medicineCuris incExchange commissionPrnewswire curis incRoche groupWashington university schoolChief executive officerKian huat limAssociate professorAim lymphomaAim leukemiaOrphan drug designationLooking statements

vimarsana © 2020. All Rights Reserved.